Translational Development Acquisition Corp.
TDAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $41 | $41 | $41 |
| - Cash | $0 | $0 | $0 |
| + Debt | $6,110,777 | $0 | $0 |
| Enterprise Value | $6,110,817 | $41 | $41 |
| Revenue | $1,065,788 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $744,919 | $0 | $0 |
| % Margin | 69.9% | – | – |
| EBITDA | -$0 | -$0 | $0 |
| % Margin | -0% | – | – |
| Net Income | -$0 | -$0 | -$0 |
| % Margin | -0% | – | – |
| EPS Diluted | -0.016 | -0.12 | -0.017 |
| % Growth | 86.5% | -589.7% | – |
| Operating Cash Flow | -$1 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 |
| Free Cash Flow | -$1 | -$0 | -$0 |